In vitro combined haemostatic efficacy of emicizumab and extended half‐life factor VIII compounds
TGA can be used to monitor combined treatment with emicizumab and either efmoroctocog alfa or efanesoctocog alfa, which is not possible with currently available FVIII reagents for the latter. As expected, there is no synergistic effect between the mimetic and FVIII at therapeutical doses. Both efmoroctocog alfa and efanesoctocog alfa show similar in vitro procoagulant activity in terms of thrombin generation.
Authors
- Christophe Nougier (ORCID: https://orcid.org/0000-0003-0578-242X)
- Yesim G. Dargaud (ORCID: https://orcid.org/0000-0002-4888-1463)
- Anne Lienhart (ORCID: https://orcid.org/0000-0001-5497-057X)
- Laurie Josset
- Stéphanie Desage (ORCID: https://orcid.org/0000-0003-0455-0248)
- Alexandre Leuci (ORCID: https://orcid.org/0000-0001-9329-8165)
- Hamdi Rezigue (ORCID: https://orcid.org/0009-0003-3765-3603)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Lille’s Cardiology Hospital (FR)
- Hospices Civils de Lyon (FR)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1111/hae.15131
- Citations
- 1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77